Paper
0
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU
Authors
Yoshitaka Honma,Nobuya Monden
Keisuke Yamazaki,Satoshi Kano,Hironaga Satake,Shigenori Kadowaki,Yoshitaka Utsumi,Tomohiko Nakatogawa,Ryo Takano,Koji Fujii,Yosuke Koroki,Junya Aoyama,Shohei Ouchi,Tetsuro Ogawa,Sharon McCarthy,Sabine Brookman‐May,Suneel Mundle,Jinhui Li,Daksh Thaper,Toshitaka Nagao
+18 authors
,Yuichiro TadaJournal
Published
Jun 28, 2024
Show more
Save
Tip0
TipSave
Abstract
To assess efficacy and safety of apalutamide plus goserelin for androgen receptor (AR)-positive, unresectable or recurrent/metastatic salivary gland carcinoma (URM-SGC).
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.